|
시장보고서
상품코드
1463060
지연성운동장애 치료제 시장 점유율, 규모, 동향, 산업 분석 보고서 : 약물별, 제품 유형별, 판매 채널별, 지역별, 부문별 예측(2024-2032년)Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 연구에 따르면, 지연성운동장애 치료제 세계 시장 규모는 2032년까지 55억 7,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
다양한 신경 및 정신병적 질환의 급격한 증가와 질환에 특화된 새로운 치료법에 대한 수요 증가가 시장 성장을 촉진하는 주요 요인으로 작용하고 있습니다. 또한, 새로운 개입을 위한 연구자 및 의료기관에 대한 재정적 지원 증가와 지연성운동장애 치료제를 포함한 헬스케어 분야의 혁신은 시장 성장을 더욱 촉진할 것으로 예측됩니다.
예를 들어, 2023년 11월 Neurocrine Biosciences는 의료진이 지연성운동장애에 대해 배우고 식별할 수 있도록 특별히 고안된 대화형 디지털 도구인 DISCOVER TD를 발표했습니다. 이 도구는 임상 전문가들과 함께 개발되었습니다.
불규칙한 도파민 분비를 유발하는 항정신병 약물로 장기 치료가 필요한 정신 질환의 사례가 전 세계적으로 증가하고 있어 효과적인 치료제에 대한 수요가 증가하고 있습니다. 또한 인지 기능의 변화를 모니터링하고 감지하며 특정 패턴을 식별하고 정보 처리 속도를 향상시키기 위한 신경심리학적 검사의 채택이 증가하고 있는 것도 시장 성장을 촉진하고 있습니다. 예를 들어, 미국 질병예방통제센터(CDC)의 보고서에 따르면 미국 성인 5명 중 1명은 정신질환을 앓고 있으며, 청소년 5명 중 1명은 평생 동안 심각한 정신질환을 앓고 있다고 합니다.
최근 미국 신경학회의 가이드라인이 업데이트되어 바르베나딘과 도이트라베나딘을 포함한 두 가지 FDA 승인 VMAT2 억제제가 포함되었습니다. 이들 약물은 레벨 A의 증거를 뒷받침하는 최초의 약물로, 주로 미국에서 지연성운동장애 치료제로 승인되었습니다.
지연성운동장애 치료제 시장 보고서 하이라이트
지연성운동장애와 그 치료제에 대한 인식이 높아지면서 바르베나딘 제제가 주목할 만한 점유율을 차지하고 있습니다.
고형제 부문은 의료 전문가들의 채택 증가와 높은 투약 효과로 인해 고형제 부문이 대부분의 점유율을 차지했습니다.
온라인 약국 부문은 온라인 구매자의 증가와 원격지를 위한 온라인 약국의 출현으로 인해 가장 높은 속도로 성장할 것으로 보입니다.
북미가 세계 시장을 주도하고 있으며, 이는 이 지역의 질병에 대한 높은 인지도와 다양한 치료 옵션, 그리고 양호한 상환 시나리오에 기인합니다.
주요 시장 기업은 Reddy Laboratories, SOM Biotech, Luye Pharma Group, Prestwick Pharmaceuticals, Sun Pharmaceuticals Industries, Allergan 등입니다.
목차
제1장 소개
제2장 주요 요약
제3장 조사 방법
제4장 지연성운동장애 치료제 세계 시장 인사이트
- 지연성운동장애 치료제 시장 - 유통 채널 현황
- 지연성운동장애 치료제 시장 역학
- 성장 촉진요인과 기회
- 연구개발의 대처
- 지연성운동장애 이환율 증가와 제품 승인 취득에 대한 기업 중점
- 성장 억제요인과 과제
- 병태생리학 이해의 한계
- 성장 촉진요인과 기회
- PESTEL 분석
- 지연성운동장애 치료제 시장 유통 채널 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 약제별 세계 시장
- 주요 조사 결과
- 소개
- Deutetrabenazine
- Valbenazine
- 기타
제6장 제품 유형별 세계 시장
- 주요 조사 결과
- 소개
- 고형 제형
- 정제
- 캡슐
- 액체 제형
- 인젝션
제7장 유통 채널별 세계 시장
- 주요 조사 결과
- 소개
- 병원 약국
- 드럭스토어와 약국
- 온라인 약국
- 기타
제8장 지역별 세계 시장
- 주요 조사 결과
- 소개
- 지연성운동장애 치료제 시장 평가, 지역, 2019-2032년
- 지연성운동장애 치료제 시장 - 북미
- 북미 : 지연성운동장애 치료제 시장, 약제별, 2019-2032년
- 북미 : 지연성운동장애 치료제 시장, 유통 채널별, 2019-2032년
- 북미 : 지연성운동장애 치료제 시장, 제품 유형별, 2019-2032년
- 지연성운동장애 치료제 시장 - 미국
- 지연성운동장애 치료제 시장 - 캐나다
- 지연성운동장애 치료제 시장 - 유럽
- 유럽 : 지연성운동장애 치료제 시장, 약제별, 2019-2032년
- 유럽 : 지연성운동장애 치료제 시장, 유통 채널별, 2019-2032년
- 유럽 : 지연성운동장애 치료제 시장, 제품 유형별, 2019-2032년
- 지연성운동장애 치료제 시장 - 영국
- 지연성운동장애 치료제 시장 - 프랑스
- 지연성운동장애 치료제 시장 - 독일
- 지연성운동장애 치료제 시장 - 이탈리아
- 지연성운동장애 치료제 시장 - 스페인
- 지연성운동장애 치료제 시장 - 네델란드
- 지연성운동장애 치료제 시장 - 러시아
- 지연성운동장애 치료제 시장 - 아시아태평양
- 아시아태평양 : 지연성운동장애 치료제 시장, 약제별, 2019-2032년
- 아시아태평양 : 지연성운동장애 치료제 시장, 유통 채널별, 2019-2032년
- 아시아태평양 : 지연성운동장애 치료제 시장, 제품 유형별, 2019-2032년
- 지연성운동장애 치료제 시장 - 중국
- 지연성운동장애 치료제 시장 - 인도
- 지연성운동장애 치료제 시장 - 말레이시아
- 지연성운동장애 치료제 시장 - 일본
- 지연성운동장애 치료제 시장 - 인도네시아
- 지연성운동장애 치료제 시장 - 한국
- 지연성운동장애 치료제 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 지연성운동장애 치료제 시장, 약제별, 2019-2032년
- 중동 및 아프리카 : 지연성운동장애 치료제 시장, 유통 채널별, 2019-2032년
- 중동 및 아프리카 : 지연성운동장애 치료제 시장, 제품 유형별, 2019-2032년
- 지연성운동장애 치료제 시장 - 사우디아라비아
- 지연성운동장애 치료제 시장 - UAE
- 지연성운동장애 치료제 시장 - 이스라엘
- 지연성운동장애 치료제 시장 - 남아프리카
- 지연성운동장애 치료제 시장 - 라틴아메리카
- 라틴아메리카 : 지연성운동장애 치료제 시장, 약제별, 2019-2032년
- 라틴아메리카 : 지연성운동장애 치료제 시장, 유통 채널별, 2019-2032년
- 라틴아메리카 : 지연성운동장애 치료제 시장, 제품 유형별, 2019-2032년
- 지연성운동장애 치료제 시장 - 멕시코
- 지연성운동장애 치료제 시장 - 브라질
- 지연성운동장애 치료제 시장 - 아르헨티나
제9장 경쟁 상황
- 확대와 인수 분석
- 확대
- 인수
- 파트너십/협업/계약/공개
제10장 기업 개요
- Allergan
- Contera Pharma
- Johnson & Johnson Services Inc.
- Lannett Co. Inc
- Luye Pharma Group
- Mitsubishi Tanabe Pharma Corporation
- Neurocrine Biosciences Inc.
- Prestwick Pharmaceuticals Inc.
- Reddy Laboratories Ltd.
- SOM Biotech
- SteriMax Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals
The global tardive dyskinesia therapeutics market size is expected to reach USD 5.57 billion by 2032, according to a new study by Polaris Market Research. The report "Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The drastic increase in the prevalence of various neurological and psychotic disorders and growing need for disease-specific novel treatment, are the leading factors propelling market's growth. Additionally, increase in financial support to the researchers and health institutes for advancing the novel intervention and bring innovations in the healthcare sector including therapeutics for tardive dyskinesia, are further anticipated to drive market's growth.
For instance, in November 2023, Neurocrine Biosciences, introduced DISCOVER TD, which is an interactive digital tool specially designed to help healthcare providers learn and identify about the tardive dyskinesia. Tool is built in collaboration with the clinical experts.
The rising cases of mental illnesses across the globe which requires prolonged treatment with antipsychotic drugs that causes irregular dopamine, fostering the demand for effective therapeutics. Also, the growing adoption of neuropsychological testing for monitoring or detecting changes in cognitive function, identifying specific patterns, and speed of information processing, are also propelling the market's growth. For instance, as per a report by the Centers for Disease Control and Prevention, nearly 1 in 5 US adults live with some form of mental illness, & nearly1 in 5 youth have seriously debilitating mental illness during their life.
Furthermore, the guideline of the American Academy of Neurology was updated recently for incorporating 2 FDA-approved VMAT2 inhibitors including valbenazine & deutetrabenazine, which has been marked as a huge milestone because they had undergone multi-center, randomized, & double-blind clinical trials. They were the first one which is going to be supported by the level A evidence and were mainly approved for the treatment of tardive dyskinesia in the United States.
Tardive Dyskinesia Therapeutics Market Report Highlights
Valbenazine segment accounted for the noteworthy share, on account of rising number of awareness campaigns about such diseases and their therapeutics
Solid dosage form segment held the majority share, driven by its rising adoption by healthcare professionals and higher effectiveness of medication
Online pharmacies segment will grow at highest pace, due to rising number of online buyers and emergence of several online pharmacies for the remotest places
North America dominated the global market, owing to region's greater awareness about disease and wider availability of treatment options, coupled with positive reimbursement scenario
The key market players include Reddy Laboratories, SOM Biotech, Luye Pharma Group, Prestwick Pharmaceuticals, Sun Pharmaceuticals Industries, and Allergan
Polaris Market Research has segmented the tardive dyskinesia therapeutics market report based on drug, product type, distribution channel, and region:
Tardive Dyskinesia Therapeutics, Drug Outlook (Revenue - USD Billion, 2019 - 2032)
- Deutetrabenazine
- Valbenazine
- Others
Tardive Dyskinesia Therapeutics, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Solid Dosage Forms
- Tablets
- Capsules
- Liquid Dosage Form
- Injection
Tardive Dyskinesia Therapeutics, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Others
Tardive Dyskinesia Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Tardive Dyskinesia Therapeutics Market Insights
- 4.1. Tardive Dyskinesia Therapeutics Market - Distribution Channel Snapshot
- 4.2. Tardive Dyskinesia Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Research and Development Initiatives.
- 4.2.1.2. Increasing prevalence of tardive dyskinesia and focus of companies on gaining product approvals are propelling market growth.
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Limited Understanding of Pathophysiology
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Tardive Dyskinesia Therapeutics Market Distribution Channel Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Tardive Dyskinesia Therapeutics Market, by Drug
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 5.3. Deutetrabenazine
- 5.3.1. Global Tardive Dyskinesia Therapeutics Market, by Deutetrabenazine, by Region, 2019-2032 (USD Billion)
- 5.4. Valbenazine
- 5.4.1. Global Tardive Dyskinesia Therapeutics Market, by Valbenazine, by Region, 2019-2032 (USD Billion)
- 5.5. Others
- 5.5.1. Global Tardive Dyskinesia Therapeutics Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Tardive Dyskinesia Therapeutics Market, by Product Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 6.3. Solid Dosage Form
- 6.3.1. Global Tardive Dyskinesia Therapeutics Market, by Solid Dosage Form, by Region, 2019-2032 (USD Billion)
- 6.4. Tablets
- 6.4.1. Global Tardive Dyskinesia Therapeutics Market, by Tablets, by Region, 2019-2032 (USD Billion)
- 6.5. Capsules
- 6.5.1. Global Tardive Dyskinesia Therapeutics Market, by Capsules, by Region, 2019-2032 (USD Billion)
- 6.6. Liquid Dosage Form
- 6.6.1. Global Tardive Dyskinesia Therapeutics Market, by Liquid Dosage Form, by Region, 2019-2032 (USD Billion)
- 6.7. Injection
- 6.7.1. Global Tardive Dyskinesia Therapeutics Market, by Injection, by Region, 2019-2032 (USD Billion)
7. Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 7.3. Hospitals Pharmacies
- 7.3.1. Global Tardive Dyskinesia Therapeutics Market, by Hospitals Pharmacies, By Region, 2019-2032 (USD Billion)
- 7.4. Drug Stores & Retail Pharmacies
- 7.4.1. Global Tardive Dyskinesia Therapeutics Market, by Drug Stores & Retail Pharmacies, By Region, 2019-2032 (USD Billion)
- 7.5. Online Pharmacies
- 7.5.1. Global Tardive Dyskinesia Therapeutics Market, by Online Pharmacies, By Region, 2019-2032 (USD Billion)
- 7.6. Others
- 7.6.1. Global Tardive Dyskinesia Therapeutics Market, by Others, By Region, 2019-2032 (USD Billion)
8. Global Tardive Dyskinesia Therapeutics Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Tardive Dyskinesia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
- 8.3. Tardive Dyskinesia Therapeutics Market - North America
- 8.3.1. North America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.3.2. North America: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.3. North America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.3.4. Tardive Dyskinesia Therapeutics Market - U.S.
- 8.3.4.1. U.S.: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.3.4.2. U.S.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.4.3. U.S.: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.3.5. Tardive Dyskinesia Therapeutics Market - Canada
- 8.3.5.1. Canada: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.3.5.2. Canada.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.5.3. Canada: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.4. Tardive Dyskinesia Therapeutics Market - Europe
- 8.4.1. Europe: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.3. Europe: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.4.4. Tardive Dyskinesia Therapeutics Market - UK
- 8.4.4.1. UK: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.4.4.2. UK.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.4.3. UK: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.4.5. Tardive Dyskinesia Therapeutics Market - France
- 8.4.5.1. France: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.4.5.2. France.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.5.3. France: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.4.6. Tardive Dyskinesia Therapeutics Market - Germany
- 8.4.6.1. Germany: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.4.6.2. Germany.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.6.3. Germany: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.4.7. Tardive Dyskinesia Therapeutics Market - Italy
- 8.4.7.1. Italy: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.4.7.2. Italy.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.7.3. Italy: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.4.8. Tardive Dyskinesia Therapeutics Market - Spain
- 8.4.8.1. Spain: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.4.8.2. Spain.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.8.3. Spain: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.4.9. Tardive Dyskinesia Therapeutics Market - Netherlands
- 8.4.9.1. Netherlands: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.4.9.2. Netherlands.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.9.3. Netherlands: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.4.10. Tardive Dyskinesia Therapeutics Market - Russia
- 8.4.10.1. Russia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.4.10.2. Russia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.10.3. Russia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.5. Tardive Dyskinesia Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.5.4. Tardive Dyskinesia Therapeutics Market - China
- 8.5.4.1. China: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.5.4.2. China.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.4.3. China: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.5.5. Tardive Dyskinesia Therapeutics Market - India
- 8.5.5.1. India: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.5.5.2. India.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.5.3. India: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.5.6. Tardive Dyskinesia Therapeutics Market - Malaysia
- 8.5.6.1. Malaysia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.5.6.2. Malaysia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.6.3. Malaysia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.5.7. Tardive Dyskinesia Therapeutics Market - Japan
- 8.5.7.1. Japan: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.5.7.2. Japan.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.7.3. Japan: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.5.8. Tardive Dyskinesia Therapeutics Market - Indonesia
- 8.5.8.1. Indonesia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.5.8.2. Indonesia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.8.3. Indonesia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.5.9. Tardive Dyskinesia Therapeutics Market - South Korea
- 8.5.9.1. South Korea: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.5.9.2. South Korea.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.9.3. South Korea: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.6. Tardive Dyskinesia Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.6.4. Tardive Dyskinesia Therapeutics Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.4.3. Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.6.5. Tardive Dyskinesia Therapeutics Market - UAE
- 8.6.5.1. UAE: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.6.5.2. UAE.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.5.3. UAE: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.6.6. Tardive Dyskinesia Therapeutics Market - Israel
- 8.6.6.1. Israel: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.6.6.2. Israel.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.6.3. Israel: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.6.7. Tardive Dyskinesia Therapeutics Market - South Africa
- 8.6.7.1. South Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.6.7.2. South Africa.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.7.3. South Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.7. Tardive Dyskinesia Therapeutics Market - Latin America
- 8.7.1. Latin America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.7.4. Tardive Dyskinesia Therapeutics Market - Mexico
- 8.7.4.1. Mexico: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.7.4.2. Mexico.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.4.3. Mexico: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.7.5. Tardive Dyskinesia Therapeutics Market - Brazil
- 8.7.5.1. Brazil: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.7.5.2. Brazil.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.5.3. Brazil: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
- 8.7.6. Tardive Dyskinesia Therapeutics Market - Argentina
- 8.7.6.1. Argentina: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
- 8.7.6.2. Argentina.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.6.3. Argentina: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Allergan
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Contera Pharma
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Johnson & Johnson Services Inc.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Lannett Co. Inc
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Luye Pharma Group
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Mitsubishi Tanabe Pharma Corporation
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Neurocrine Biosciences Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Prestwick Pharmaceuticals Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Reddy Laboratories Ltd.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. SOM Biotech
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. SteriMax Inc.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Sun Pharmaceutical Industries Ltd.
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Teva Pharmaceutical Industries Ltd.
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Valeant Pharmaceuticals
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
샘플 요청 목록